Evidence map›Paper›PMID 39965128›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Behavioral Abnormalities, Cognitive Impairments, Synaptic Deficits, and Gene Replacement Therapy in a CRISPR Engineered Rat Model of 5p15.2 Deletion Associated With Cri du Chat Syndrome.

Jingjing Shen, Yan Wang, Yang Liu, Junying Lan, Shuang Long, Yingbo Li, Di Chen, Peng Yu, Jing Zhao, Yongjun Wang and 2 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Roles and regulation of δ-catenin in tumorigenesis and neuronal diseases.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jingjing ShenInstitute of Neuroscience, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Yan WangInstitute of Neuroscience, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Yang LiuChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Junying LanBasic and Translational Medicine Center, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Shuang LongInstitute of Neuroscience, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Yingbo LiInstitute of Neuroscience, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Di ChenInstitute of Neuroscience, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Peng YuChinese Institutes for Medical Research, Capital Medical University, Beijing, 100069, China.
Jing ZhaoInstitute of Neuroscience, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Yongjun WangChina National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Shali WangInstitute of Neuroscience, School of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Feng YangBasic and Translational Medicine Center, China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.ORCID https://orcid.org/0000-0003-1275-6641

Funding

Beijing Natural Science Foundation IS23097Beijing Natural Science Foundation L222077
6 · The paper itself

Abstract

The Cri du Chat Syndrome (CdCS), a devastating genetic disorder caused by a deletion on chromosome 5p, faces challenges in finding effective treatments and accurate animal models. Using CRISPR-Cas9, a novel CdCS rat model with a 2q22 deletion is developed, mirroring a common genetic alteration in CdCS patients. This model exhibits pronounced deficits in social behavior, cognition, and anxiety, accompanied by neuronal abnormalities and immune dysregulation in key brain regions such as the hippocampus and medial prefrontal cortex (mPFC). The immunostaining and RNA-seq analyses provide new insights into CdCS pathogenesis, revealing inflammatory and immune processes. Importantly, it is demonstrated that early gene replacement therapy with AAV-Ctnnd2 alleviates cognitive impairments in CdCS rats, highlighting the potential for early intervention. However, the effectiveness of this therapy is confined to the early developmental stages and does not fully restore all CdCS symptoms. The findings deepen the understanding of CdCS pathogenesis and suggest promising therapeutic directions.

Indexed as

Cognitive DysfunctionCri-du-Chat SyndromeGenetic TherapyAnimalsBehavior, AnimalChromosome DeletionCRISPR-Cas SystemsDisease Models, AnimalMaleRatsSocial Behavior5p15.2 deletionCri du Chat syndromeCtnnd2gene therapyrat model

Identifiers

PMID39965128
PMCPMC11984882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.